Division of Hematology and Medical Oncology

Active Projects: 75

Project Investigator All Organizations Start date End date
CARAVAN: Checkpoint-Radiation-Vaccine Neoadjuvant Trial for Metastatic Prostate Cancer Lawrence Fong, MD Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center
Real-World Treatment Patterns and Associated Outcomes Among Patients with Advanced Progressive Pancreatic Neuroendocrine Tumors Emily Bergsland, MD Division of Hematology and Medical Oncology
Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma Division of Hematology and Medical Oncology
The Breast Cancer Clinical Trials Consortium Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination with Bevacizumab versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma Lawrence Fong, MD Division of Hematology and Medical Oncology
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment Eric J. Small, MD Division of Hematology and Medical Oncology
Phase III Study Evaluating Palbociclib (PD-0332991), a Cycline-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone-Receptor-Positive, HER2-Normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy "Penelope" Hope Rugo, MD Division of Hematology and Medical Oncology
Targeting MYC-Driven Cell Cycle Progression in Neuroendocrine Prostate Cancer with Gallium Citrate PET as a Novel Biomarker of MYC Transcriptional Activity Rahul R. Aggarwal, MD Division of Hematology and Medical Oncology
A Phase II, Open Study of the Clinical Activity, Safety and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB-2-Overexpressing Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
Study of Paclitaxel eith GDC-0941 vs Paclicaxel with placebo in patients with locally recurrent or Metastatic Breast Cancer Michelle E. Melisko, MD Division of Hematology and Medical Oncology
The Prostate Cancer Clinical Trials Consortium: Clinical Research Site Application Charles J. Ryan, MD Division of Hematology and Medical Oncology
GSK Zoster2-Observer blind study to evaluate efficacy, safety, and immunogenictiy of GSK Biologicals Herpes Zoster vaccine Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) Alan P. Venook, MD Division of Hematology and Medical Oncology
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease Donald Abrams, MD Division of Hematology and Medical Oncology
Metastatic escape mechanisms in TKI resistant lung cancer Division of Hematology and Medical Oncology
A Phase I/II Study Evaluating Microwave Hyperthermia and Thermodox (Lyso-Thermosensitive Liposomal Doxorubicin) in Patients with Breast Cancer Recurrence at the Chest Wall (DIGNITY) Hope Rugo, MD Division of Hematology and Medical Oncology
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer Eric J. Small, MD Division of Hematology and Medical Oncology
Prostate Cancer Foundation Young Investigator Award Division of Hematology and Medical Oncology
A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164) Division of Hematology and Medical Oncology, Helen Diller Family Comprehensive Cancer Center
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
Service Agreement - HALO-109-301 Study Margaret A. Tempero, MD Division of Hematology and Medical Oncology
A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-Optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients with Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence Hope Rugo, MD Division of Hematology and Medical Oncology
Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment Pamela N. Munster, MD Division of Hematology and Medical Oncology
An Open-label, Multi-center, Extension Study of NKTR 102 in Subjects Previously Enrolled in NKTR-102 Studies Pamela N. Munster, MD Division of Hematology and Medical Oncology
The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell transplantation (autoSCT) Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer Rahul R. Aggarwal, MD Division of Hematology and Medical Oncology
Phase 3 study of PD-0332991 (Oral CDK4/6 inhibitor) plus Letrozole versus placebo plus Letrozole for postmenopausal women with ER (+), HER2 (-) breast cancer who have not received prior systemic anti cancer therapies Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Division of Hematology and Medical Oncology
Phase 3 trial Of Fulvestrant with or without Palbociclib +/- Goserelin in women with hormone receptor-positive, Her2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy Hope Rugo, MD Division of Hematology and Medical Oncology
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (CDX011-04) Michelle E. Melisko, MD Division of Hematology and Medical Oncology
A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer. Hope Rugo, MD Division of Hematology and Medical Oncology
Phase II, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutumide with Trastuzumab in Subjects with Her2+ AR+ Metastatic or Locally Advanced Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients with Advanced Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More than 2 Prior Chemotherapy Hope Rugo, MD Division of Hematology and Medical Oncology
Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer. Hope Rugo, MD Division of Hematology and Medical Oncology
Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumor Malignancies that have BRCA Mutations or Triple Negative Metastatic Breast Cancer Pamela N. Munster, MD Division of Hematology and Medical Oncology
Phase 1b/2 Study of MLN0128 (Dual TORC 1/2 Inhibitor) with Exemestane or Fulvestrant Therapy in Postmenopausal with ER+/HER2- Advanced or Metastatic Breast Cancer that has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestra Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma Division of Hematology and Medical Oncology
A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy Emily Bergsland, MD Division of Hematology and Medical Oncology
Clinical Performance, Efficacy and Safety of the DigniCap System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients with Early Stage Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma Division of Hematology and Medical Oncology
Immunotherapy of human bladder cancer Lawrence Fong, MD Division of Hematology and Medical Oncology
A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study- TBCRC 029 Hope Rugo, MD Division of Hematology and Medical Oncology
Characterization of a novel role for Hippo-YAP pathway signaling in cancer progression and therapy resistance Trever G. Bivona, MD, PhD Division of Hematology and Medical Oncology
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Non-small Cell Lung Carcinoma Division of Hematology and Medical Oncology
Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor Division of Hematology and Medical Oncology
A Study of the Safety, Immunopharmacodymics and Anti-TumorActivity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma Margaret A. Tempero, MD Division of Hematology and Medical Oncology
An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation Division of Hematology and Medical Oncology
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis. Jo Chien, MD Division of Hematology and Medical Oncology
ADXS31-142 in Combination with Pembrolizumab (MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer Lawrence Fong, MD Division of Hematology and Medical Oncology
An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma Division of Hematology and Medical Oncology
A Phase 1 Study to Evaluate the Effect of NKTR-102 for Injection (etirinotecan pegol) on the QT/QTc Interval in Patients With Advanced or Metastatic Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
A Phase 2 Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma (FLC) Division of Hematology and Medical Oncology
Mount Zion Health Fund - Harold Dobbs Cancer Research Fund Alan P. Venook, MD Division of Hematology and Medical Oncology
A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies Division of Hematology and Medical Oncology
Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination with Doxorubicin HCl Liposomal (Doxil®) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-cell Lymphoma Ai Z. Weiyun, MD, PhD Division of Hematology and Medical Oncology
A Phase 2, Randomized, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
Phase 1b Study of SAR650984 in Combo with Lenalidomide and Dexa for Treatment of Relapsed or Refractory Multiple Myeloma Thomas G. Martin, MD Division of Hematology and Medical Oncology
An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer Katherine Van Loon Steitz, MD, MPH Global Health Sciences Faculty Affiliate, Division of Hematology and Medical Oncology
A Phase I/IIa Study of Safety and Efficacy of Alpharadin® with Docetaxel in Patients with Bone Metastases From Castration Resistant Prostate Cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer Division of Hematology and Medical Oncology
Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies Pamela N. Munster, MD Division of Hematology and Medical Oncology
A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Patients with Relapsed/Refractory Multiple Myeloma Division of Hematology and Medical Oncology
An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men with Localized Prostate Cancer Undergoing Radical Prostatectomy Lawrence Fong, MD Division of Hematology and Medical Oncology
A Phase Ib Dose Escalation Trial of Carfilzomib plus Bendamustine and Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
Phase II Single Agent Study of Selinexor (KPT-330) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy with Abiraterone Charles J. Ryan, MD Division of Hematology and Medical Oncology
CC# 159518 A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with a Solid Tumor Cancer Pamela N. Munster, MD Division of Hematology and Medical Oncology
Phase III Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy vs Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Locally Advanced or Metastatic Non Small-Cell Lung Cancer Division of Hematology and Medical Oncology
Phase 1 Open Label, Multi-center Study to Assess the Safety, tolerability and Pharmacokinetics of Orally administered CUDC-907, an HDAC and PI3K Inhibitor in Subjects with Advanced/ Relapsed Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
CC 152512: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
Multiple Myeloma Research Foundation Tissue Banking Agreement Thomas G. Martin, MD Division of Hematology and Medical Oncology
CC#15987 - Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-meso-19 Gene Therapy Products in Cancer Studies Division of Hematology and Medical Oncology

Archived Projects: 74

Project Investigator All Organizations Start date End date
Identification of the CD8+Cell Anti-HIV Factor (CAF) Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
JCF/Hellman Grant Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
JCF/Bransten Grant Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Role of Innate Immunity in Controlling HIV Infection Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
UCSF AIDS Research Training Program Jay A. Levy, MD Division of Hematology and Medical Oncology
Immunologic and Virologic Features of Early HIV Infection Jay A. Levy, MD Division of Hematology and Medical Oncology
A Phase II Clinical Trial of Pembrolizumab as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) Hope Rugo, MD Division of Hematology and Medical Oncology
Role of Innate Immunity in Controlling HIV Infection Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Molecular Epidemiology of the Human Immunodeficiency Virus in Mexico Jay A. Levy, MD Division of Hematology and Medical Oncology
Role of Innate Immunity in Controlling HIV Infection Jay A. Levy, MD Division of Hematology and Medical Oncology
Identification of the CD8+ Cell Antiviral Factor (CAF) Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Subcontract from UFL Prime: HIV/FIV-Cat-Model: A model to identify vaccine epitopes Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Role of Innate Immunity in Controlling HIV Infection Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Innate Immunity and Autophagy in Elite Controllers Michael S. Killian, PhD, MPH Division of Hematology and Medical Oncology
Chinese Fellowship Jay A. Levy, MD Division of Hematology and Medical Oncology
Identification of the CD8+ Cell Anti-HIV Factor (CAF) Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Protection from HIV Infection in Intravenous Drug Users Jay A. Levy, MD Division of Hematology and Medical Oncology
Open-Label, Expanded Access Protocol of BSI-201 in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative Metastatic Breast Cancer Hope Rugo, MD Division of Hematology and Medical Oncology
HIV cure with CCR5 (-) human IPS hematopoietic stem cells Jay A. Levy, MD Division of Hematology and Medical Oncology
Compassionate Use of Marqibo for the Treatment of Refractory T-Cell Acute Lymphoblastic Leukemia Lawrence D. Kaplan, MD Division of Hematology and Medical Oncology
Sanofi-Aventis SAR650894 Program - Clinical Component Thomas G. Martin, MD Division of Hematology and Medical Oncology
Sanofi-Aventis SAR650894 Program - Research Component Thomas G. Martin, MD Division of Hematology and Medical Oncology
Individually Optimized Conditioning Using PK-directed Dose Adjustment of Once Daily IV Busulfan, Followed by Autologous Hematopoietic Stem Cell Transplant Ai Z. Weiyun, MD, PhD Division of Hematology and Medical Oncology
Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK) in Patients with Advanced Cancer Pamela N. Munster, MD Division of Hematology and Medical Oncology
Phase 1b, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MEGF0444A, A Humanized 1gG1 Antibody in Combination with Bevacizumab with or without Paclitaxel in Patients with Locally Advanced or Metastatic Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
A Phase I Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients with Advanced Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
Chronic Effects of Chemotherapy on Brain Function Hope Rugo, MD Division of Hematology and Medical Oncology
Compassionate Use of Marqibo for the Treatment of Refractory Lymphoblastic Leukemia/Leukemia Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
Study of AMG 479 with Exemestane or Fulvestrant in Postmenopausal Women with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Michelle E. Melisko, MD Division of Hematology and Medical Oncology
BEACON Study (BrEAst Cancer Outcomes with NKTR-102): Phase 3 Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated with Anthracycline, a Taxane and Capecitabine Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK2126458 in Subjects with Solid Tumors or Lymphoma Pamela N. Munster, MD Division of Hematology and Medical Oncology
Research Fellowship Grant Alan P. Venook, MD Division of Hematology and Medical Oncology
A Phase 1B, Multi-Center, Open Label, Dose Escalation Study of Oral LDE225 in Combination with BKM120 in Patients with Advanced Solid Tumors Pamela N. Munster, MD Division of Hematology and Medical Oncology
A Pilot Study of FOLFOX in Combination with Bevacizumab in Patients with Advanced Neuroendocrine Tumors Emily Bergsland, MD Division of Hematology and Medical Oncology
Phase 1 Open-Label First-in-Human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Malignancies That Are Refractory to All Standard Pamela N. Munster, MD Division of Hematology and Medical Oncology
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase Ib Dose Escalation/Randomized Phase II, Multicenter, Open-label Study of BYL719 in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Pamela N. Munster, MD Division of Hematology and Medical Oncology
AIDS Malignancies Consortium Lawrence D. Kaplan, MD Division of Hematology and Medical Oncology
Identification of the CD8 Cell Anti-HIV Factor (CAF) Jay A. Levy, MD Division of Hematology and Medical Oncology
Targeting Adaptive Pathways in Resistant CRPC Eric J. Small, MD Division of Hematology and Medical Oncology
Support for a Multiple Myeloma Project Coordinator Division of Hematology and Medical Oncology
Phase IA, Multicenter, Open-label Dose Escalation Study of Oral BYL719, in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Hope Rugo, MD Division of Hematology and Medical Oncology
Phase I Study of INC280 plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer. Division of Hematology and Medical Oncology
A Multicenter Phase I/II Trial of Abiraterone + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
Beacon (Breast Cancer Outcomes with Nktr-102): a Phase 3 Study of Nktr-102 Versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline, Taxane and Capecitabine Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase II, Single Arm Study of the Use of Steroid-Based Mouthwash to Prevent Stomatitis in Postmenopausal Women with Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated with Everolimus plus Exemestane. Hope Rugo, MD Division of Hematology and Medical Oncology
Cellular mechanisms of resistance to chemotherapy and the impact of immune modulating therapy, and molecular characterization of circulating tumor cells (CTCs) in patients with advanced breast cancer (ABC) Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases (TBCRC 022) Michelle E. Melisko, MD Division of Hematology and Medical Oncology
TBCRC 22: A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases Michelle E. Melisko, MD Division of Hematology and Medical Oncology
Master Member Agreement: Translational Breast Cancer Research Consortium Hope Rugo, MD Division of Hematology and Medical Oncology
Genetic Determinants of Capecitabine Toxicity Hope Rugo, MD Division of Hematology and Medical Oncology
Effect of an embedded palliative care program on the unmet needs of patients with metastatic breast cancer. Melanie C. Majure, MD Division of Hematology and Medical Oncology
The Breast Cancer Clinical Trials Consortium Hope Rugo, MD Division of Hematology and Medical Oncology
Targeting the c-Met/HGF Axis in acute Myeloid Leukemia Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
The role of HDAC2 in hormone therapy resistance Pamela N. Munster, MD Division of Hematology and Medical Oncology
Enhancing the Efficacy of Chemotherapy in Triple Negative/Basal-like Breast Cancer by Targeting Macrophages Hope Rugo, MD Division of Hematology and Medical Oncology
PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment Michelle E. Melisko, MD Division of Hematology and Medical Oncology
Pancreatic Cancer Research Pilot Project Margaret A. Tempero, MD Division of Hematology and Medical Oncology
Evaluation of Pomalidomide in Combination with High Dose Dexamethasone and Oral Cyclophosphamide in Patients with Relapsed and Refractory Myeloma Thomas G. Martin, MD Division of Hematology and Medical Oncology
Phase II study of letrozole with or without BYL719 or buparlisib, for the neoadjuvant treatment of postmenopausal women with hormone receptor-positive HER2-negative breast cancer Hope Rugo, MD Division of Hematology and Medical Oncology
Dar es Salaam ESCC Case-Control Study Katherine Van Loon Steitz, MD, MPH Division of Hematology and Medical Oncology
Study of the histone deacetylase inhibitor Panobinostat (LBH589) in combination with standard dose Cytarabine and Daunorubicin for older patients with untreated acute Mmyeloid leukemia or advanced myelodysplasia Charalambos (Babis) Andreadis, MD Division of Hematology and Medical Oncology
Prostate Cancer Therapeutic Clinical Investigation "First in Man" Eric J. Small, MD Division of Hematology and Medical Oncology
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment Trever G. Bivona, MD, PhD Division of Hematology and Medical Oncology
Tumor Recurrence and Drug Resistance in Non-Small Cell Lung Cancer Through Modulation of the Cytoskeleton and Activation of YAP Division of Hematology and Medical Oncology
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination with Abiraterone in Chemotherapy Naïve Subjects with Bone-Metastatic Castration-Resistant Prostate Cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
An Open-Label, Multicenter Extension Study of Trastuzumab-MCC-DM1 in Patients Previously Treated with T-DM1 in a Genentech-Sponsored T-DM1 Study Hope Rugo, MD Division of Hematology and Medical Oncology
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer Pamela N. Munster, MD Division of Hematology and Medical Oncology
HIV cure with CCR5 negative human IPS hematopoietic stem cells Jay A. Levy, MD Division of Hematology and Medical Oncology, AIDS Research Institute
Serum Androgens as Predictors of Survival in Metastatic Prostate Cancer Charles J. Ryan, MD Division of Hematology and Medical Oncology
A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. Hope Rugo, MD Division of Hematology and Medical Oncology
CC#14952: Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors Hope Rugo, MD Division of Hematology and Medical Oncology
The PROMOTE Program: Precision Oncology and Molecular Targeting in Advanced Prostate Cancer Advancing the Promise of the PCF/SU2C/AACR West Coast Prostate Cancer Dream Team Eric J. Small, MD Division of Hematology and Medical Oncology